Horwitz K B
Dept. of Medicine, University of Colorado Health Sciences Center, Denver 80262.
Breast Cancer Res Treat. 1993;26(2):119-30. doi: 10.1007/BF00689685.
At least half of all advanced breast cancers are positive for estrogen receptor (ER) and progesterone receptor (PR), but many nevertheless fail to respond to endocrine therapy. Studies of breast cancer cell lines and breast tumor specimens are beginning to reveal molecular heterogeneity of the receptors in subpopulations of these cells, leading to altered receptor function and sometimes to hormone resistance. Here we will review the data on molecular and cellular heterogeneity involving ER and PR, and possible underlying mechanisms of resistance to tamoxifen and progestins.
至少一半的晚期乳腺癌雌激素受体（ER）和孕激素受体（PR）呈阳性，但仍有许多患者对内分泌治疗无反应。对乳腺癌细胞系和乳腺肿瘤标本的研究开始揭示这些细胞亚群中受体的分子异质性，导致受体功能改变，有时还会产生激素抵抗。在此，我们将综述有关ER和PR分子及细胞异质性的数据，以及对他莫昔芬和孕激素耐药的可能潜在机制。
